Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.

Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.

Lian Y, Yin H, Pollak MN, Carrier S, Platt RW, Suissa S, Azoulay L. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. Eur Urol. 2016 Nov;70(5):808-815.

View All Publications